Plus   Neg

Manz AG Posts Wider Loss In 9-month, Revenue Down 6.5%; Revises Guidance

Manz AG (MANZF.PK) reported a net loss of 11.4 million euros in the first nine months of 2019 compared to a loss of 4.9 million euros, last year. Loss per share was 1.44 euros compared to a loss of 0.62 euros per share. EBITDA increased to 5.8 million euros from 3.7 million euros. Earnings before interest and taxes (EBIT) was negative at 7.7 million euros compared to a negative EBIT of 2.4 million euros.

In the first nine months of 2019, Group revenues were at 198.2 million euros, 6.5 percent below previous year. The company said the decline in sales reflects the ongoing customer project delays in the Solar segment, as well as the unmet need for major investments from the electromobility segment in the development of European battery production.

Manz AG's Managing Board has corrected its previous earnings forecast due to the overall economic development. The Management Board now expects a positive EBITDA margin in the lower single-digit percentage range and a negative EBIT in the upper single-digit million range for the 2019 financial year, with revenues slightly below the previous year's level.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
eBay Inc. (EBAY) Wednesday reported a fourth-quarter profit that trumped Wall Street analysts' estimates, as did revenues. However, shares of the company slipped over 5% after the company issued a weak outlook for the first quarter. eBay's fourth-quarter profit dropped to $558 million or $0.69 per... Apple Inc. (AAPL) Wednesday reported a first-quarter profit that trumped Wall Street estimates, as the iPhone maker reported its "highest quarterly revenue ever" driven by strong demand for its iPhone 11 and 11 Pro models during the holiday season. The tech giant also issued a strong revenue outlook... New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry.
Follow RTT